183 related articles for article (PubMed ID: 12727930)
21. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
23. Human pituitary null cell adenomas and oncocytomas in vitro: effects of adenohypophysiotropic hormones and gonadal steroids on hormone secretion and tumor cell morphology.
Asa SL; Cheng Z; Ramyar L; Singer W; Kovacs K; Smyth HS; Muller P
J Clin Endocrinol Metab; 1992 May; 74(5):1128-34. PubMed ID: 1569159
[TBL] [Abstract][Full Text] [Related]
24. Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells.
An J; Pei X; Zang Z; Zhou Z; Hu J; Zheng X; Zhang Y; He J; Duan L; Shen R; Zhang W; Zhu F; Li S; Yang H
Oncotarget; 2017 Jun; 8(23):37538-37549. PubMed ID: 28380462
[TBL] [Abstract][Full Text] [Related]
25. Effect of vasoactive intestinal polypeptide (VIP) on growth hormone (GH) and prolactin (PRL) release and cell morphology in human pituitary adenoma cell cultures.
Fazekas I; Bácsy E; Varga I; Slowik F; Bálint K; Pásztor E; Czirják S; Gláz E
Folia Histochem Cytobiol; 2000; 38(3):119-27. PubMed ID: 10970071
[TBL] [Abstract][Full Text] [Related]
26. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665
[TBL] [Abstract][Full Text] [Related]
27. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas.
Rubinfeld H; Hadani M; Barkai G; Taylor JE; Culler MD; Shimon I
J Clin Endocrinol Metab; 2006 Jun; 91(6):2257-63. PubMed ID: 16595604
[TBL] [Abstract][Full Text] [Related]
28. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.
Zhou C; Jiao Y; Wang R; Ren SG; Wawrowsky K; Melmed S
J Clin Invest; 2015 Apr; 125(4):1692-702. PubMed ID: 25774503
[TBL] [Abstract][Full Text] [Related]
29. Gonadotroph adenoma with secondary hypersecretion of testosterone.
Chamoun R; Layfield L; Couldwell WT
World Neurosurg; 2013 Dec; 80(6):900.e7-11. PubMed ID: 23201183
[TBL] [Abstract][Full Text] [Related]
30. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
31. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
32. Comparison of hormonal secretory behavior of gonadotroph cell adenomas in vivo and in culture.
Snyder PJ; Bashey HM; Phillips JL; Gennarelli TA
J Clin Endocrinol Metab; 1985 Dec; 61(6):1061-5. PubMed ID: 2414310
[TBL] [Abstract][Full Text] [Related]
33. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
[TBL] [Abstract][Full Text] [Related]
34. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
Wayman NS; Hattori Y; McDonald MC; Mota-Filipe H; Cuzzocrea S; Pisano B; Chatterjee PK; Thiemermann C
FASEB J; 2002 Jul; 16(9):1027-40. PubMed ID: 12087064
[TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization.
Murata T; He S; Hangai M; Ishibashi T; Xi XP; Kim S; Hsueh WA; Ryan SJ; Law RE; Hinton DR
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2309-17. PubMed ID: 10892878
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
38. GH and PRL gene expression by nonradioisotopic in situ hybridization in TSH-secreting pituitary adenomas.
Sanno N; Teramoto A; Matsuno A; Takekoshi S; Osamura RY
J Clin Endocrinol Metab; 1995 Aug; 80(8):2518-22. PubMed ID: 7543115
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of insulin-like growth factor 1 on the hormonal product and proliferation of glycoprotein-secreting human pituitary adenomas.
Atkin SL; Landolt AM; Jeffreys RV; Hipkin L; Radcliffe J; Squire CR; White MC
J Clin Endocrinol Metab; 1993 Oct; 77(4):1059-66. PubMed ID: 7691862
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of transcription factor pit-1 to target tumoral somatolactotroph cells.
Roche C; Rasolonjanahary R; Thirion S; Goddard I; Fusco A; Figarella-Branger D; Dufour H; Brue T; Franc JL; Enjalbert A; Barlier A
Hum Gene Ther; 2012 Jan; 23(1):104-14. PubMed ID: 21942649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
